Comparative Pharmacology
Head-to-head clinical analysis: VONTROL versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VONTROL versus ZUPLENZ.
VONTROL vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VONTROL (trimethobenzamide) acts centrally to inhibit the chemoreceptor trigger zone (CTZ) in the medulla oblongata, thereby suppressing nausea and vomiting. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and serotonin 5-HT3 receptors.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
10 mg orally twice daily; maximum 20 mg/day.
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
12 hours; prolonged in renal impairment (up to 24 hours in ESRD)
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Renal: 60% unchanged; fecal: 30% (biliary); hepatic metabolism: 10%
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category C
Category C
Antiemetic
Antiemetic